Cargando…
The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy
Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting on the role of the chronologically preceding agents, interferon-alfa and lamivudine. The impact...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066383/ https://www.ncbi.nlm.nih.gov/pubmed/27729632 http://dx.doi.org/10.3350/cmh.2016.0045 |
_version_ | 1782460475527659520 |
---|---|
author | Varbobitis, Ioannis Papatheodoridis, George V. |
author_facet | Varbobitis, Ioannis Papatheodoridis, George V. |
author_sort | Varbobitis, Ioannis |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting on the role of the chronologically preceding agents, interferon-alfa and lamivudine. The impact of interferon-alfa on the incidence of HCC is clearer in Asian patients and those with compensated cirrhosis, as several meta-analyses have consistently shown HCC risk reduction, compared to untreated patients. Nucleos(t)ide analogues also seem to have a favorable impact on the HCC incidence when data from randomized or matched controlled studies are considered. Given that the high-genetic barrier agents, entecavir and tenofovir, are mainly used in CHB because of their favorable effects on the overall long-term outcome of such patients, the most clinically important challenge is the identification of patients who require close HCC surveillance despite on-therapy virological remission. Several risk scores have been developed for HCC prediction in CHB patients. Most of them, such as GAG-HCC, CU-HCC and REACH-B, have been developed and validated in Asian untreated and treated CHB patients, but they do not seem to offer good predictability in Caucasian CHB patients for whom a newer score, PAGE-B, has been recently developed. |
format | Online Article Text |
id | pubmed-5066383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | The Korean Association for the Study of the Liver |
record_format | MEDLINE/PubMed |
spelling | pubmed-50663832016-10-17 The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy Varbobitis, Ioannis Papatheodoridis, George V. Clin Mol Hepatol Review Hepatocellular carcinoma (HCC) is a primary concern for patients with chronic hepatitis B (CHB). Antiviral therapy has been reasonably the focus of interest for HCC prevention, with most studies reporting on the role of the chronologically preceding agents, interferon-alfa and lamivudine. The impact of interferon-alfa on the incidence of HCC is clearer in Asian patients and those with compensated cirrhosis, as several meta-analyses have consistently shown HCC risk reduction, compared to untreated patients. Nucleos(t)ide analogues also seem to have a favorable impact on the HCC incidence when data from randomized or matched controlled studies are considered. Given that the high-genetic barrier agents, entecavir and tenofovir, are mainly used in CHB because of their favorable effects on the overall long-term outcome of such patients, the most clinically important challenge is the identification of patients who require close HCC surveillance despite on-therapy virological remission. Several risk scores have been developed for HCC prediction in CHB patients. Most of them, such as GAG-HCC, CU-HCC and REACH-B, have been developed and validated in Asian untreated and treated CHB patients, but they do not seem to offer good predictability in Caucasian CHB patients for whom a newer score, PAGE-B, has been recently developed. The Korean Association for the Study of the Liver 2016-09 2016-09-25 /pmc/articles/PMC5066383/ /pubmed/27729632 http://dx.doi.org/10.3350/cmh.2016.0045 Text en Copyright © 2016 by The Korean Association for the Study of the Liver This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Varbobitis, Ioannis Papatheodoridis, George V. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy |
title | The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy |
title_full | The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy |
title_fullStr | The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy |
title_full_unstemmed | The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy |
title_short | The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy |
title_sort | assessment of hepatocellular carcinoma risk in patients with chronic hepatitis b under antiviral therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066383/ https://www.ncbi.nlm.nih.gov/pubmed/27729632 http://dx.doi.org/10.3350/cmh.2016.0045 |
work_keys_str_mv | AT varbobitisioannis theassessmentofhepatocellularcarcinomariskinpatientswithchronichepatitisbunderantiviraltherapy AT papatheodoridisgeorgev theassessmentofhepatocellularcarcinomariskinpatientswithchronichepatitisbunderantiviraltherapy AT varbobitisioannis assessmentofhepatocellularcarcinomariskinpatientswithchronichepatitisbunderantiviraltherapy AT papatheodoridisgeorgev assessmentofhepatocellularcarcinomariskinpatientswithchronichepatitisbunderantiviraltherapy |